News & Updates

A 20-year nested case–control study in China has shown sequential and temporal changes in biomarkers 6–18 years before diagnosis of Alzheimer’s disease (AD). Accelerated changes in cerebrospinal fluid (CSF) biomarkers were found after the onset of cognitive impairment, followed by plateaus at AD diagnosis. 

Endovascular thrombectomy (EVT) in addition to medical care results in significantly improved functional outcomes at 1 year in acute ischaemic stroke patients with a large core infarct compared with medical care alone, as shown in the SELECT2 study. This benefit persists across ischaemic core strata on imaging.

Treatment with lecanemab continue to provide benefits to patients with early Alzheimer’s disease (AD) through 24 months, according to the results of the ongoing open-label extension study of Clarity AD. Those who have been treated much later also show disease improvements.

A study in Singapore provides further evidence regarding the benefits of poststroke rehabilitation in improving function, reducing disability, and discharging patients. In addition, the results show that body mass index (BMI) in any category does not predict the ability to attain functional independence following inpatient rehabilitation.

Daily use of the oral calcitonin gene-related peptide (CGRP) receptor antagonist atogepant to prevent migraine is associated with a favourable safety profile and sustained improvements in efficacy outcomes, according to the 52-week data from an ongoing, open-label, 156-week safety extension study.

Children and adolescents with Tourette syndrome (TS) may benefit from ecopipam, a first-in-class selective dopamine-1 (D1) receptor antagonist, as it reduced the number of tics and level of daily interference in a post hoc analysis of the phase IIb D1AMOND trial.

A pilot study presented at AAN 2024 revealed that a tandem cycling programme may improve the overall health and wellbeing of individuals with Parkinson’s disease (PD) and their care partners.